Resumen
The complex interaction between the immune system, the tumor and the microenvironment in pancreatic ductal adenocarcinoma (PDA) leads to the resistance of PDA to immunotherapy. To overcome this resistance, combination immunotherapy is being proposed. However, rational combinations that target multiple aspects of the complex anti-tumor immune response are warranted. Novel clinical trials will investigate and optimize the combination immunotherapy for PDA.
| Idioma original | English (US) |
|---|---|
| Número de artículo | 31 |
| Publicación | Chinese Clinical Oncology |
| Volumen | 6 |
| N.º | 3 |
| DOI | |
| Estado | Published - jun 1 2017 |
| Publicado de forma externa | Sí |
ASJC Scopus subject areas
- Oncology
Huella
Profundice en los temas de investigación de 'Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma'. En conjunto forman una huella única.Citar esto
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS